MAGNESIUM METALLICUM
Chemotherapeutic Agent Toxicity
Alliance for Clinical Trials in OncologySmall moleculePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Chemotherapeutic Agent Toxicity cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Endeavor Health | Phase 3 | BB |
METHOTREXATE Instituto do Cancer do Estado de São Paulo | Phase 2 | BB |
FILGRASTIM Centre Francois Baclesse | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Zhiyong Yu | Phase 2/3 | BB |
Cytosin-Arabinosid Instituto do Cancer do Estado de São Paulo | Phase 3 | BB |
View all 21 →
Same molecule, other indications
MAGNESIUM METALLICUM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →